脑转移作为肺癌最常见的转移途径之一,严重影响着患者的预后情况。面对这一挑战,洛拉替尼凭借其特有的小分子大环酰胺结构,以卓越的血脑屏障穿透性为改善ALK阳性晚期NSCLC患者的脑转移问题提供了保障。CROWN研究36.7个月的随访数据显示,对于基线有脑转移的人群,洛拉替尼和克唑替尼组经BICR评估的颅内ORR分别为83.3% vs 23.3%,完全缓解(CR)率分别为72.2% vs 7.7%[1];对于基线无脑转移人群,洛拉替尼组的112例患者中仅1例出现颅内进展,3年无颅内进展率高达99.1%,并且使颅内疾病进展风险下降了98%(HR=0.02)[1]。这两组数据强调了洛拉替尼在防治脑转移方面的明显优势,并且进一步体现了其在一线治疗中能够为患者带来的确切疗效。
[1] Solomon BJ,et al.Presented at 2022 AACR. Abstract #CT223.
[2] Solomon BJ, et al. Lancet Respir Med. 2022 Dec 16:S2213-2600(22)00437-4.
[3]Zhou Q, et al. 992P Updated analyses from the CROWN study of first-line lorlatinib vs crizotinib in Asian patients with ALK-positive non-small cell lung cancer. ESMO 2022.
[4]Christine Garcia,et al. Comparative efficacy and safety of lorlatinib vs alectinib and brigatinib using matching adjusted indirect comparisons (MAIC). 2023 WCLC. EP12.02-06
[5]Nagasaka M, Ou SI. CROWN 2022 Second Interim Updates: When Will Be the Coronation of Lorlatinib? J Thorac Oncol. 2023 Feb;18(2):139-142.
[6] Liu G, et al. Ann Oncol. 2023;34(Supplement 2):S781-2.